Filing Flows › Co-Diagnostics (CODX) › Q3 2025
Co-Diagnostics (CODX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 13, 2025
Co-Diagnostics (CODX) reported revenue of $145K for the third quarter 2025 (Q3 2025), -77% from a year earlier and -11% from the quarter before.
Co-Diagnostics, Q3 2025: revenue $145K (-77% year over year), net loss $5.9M, operating cash flow −$5.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $145K | -11% | -77% |
| Operating profit | −$7.0M | — | — |
| Net earnings | −$5.9M | — | — |
| Operating cash flow | −$5.9M | — | — |
What changed
Revenue was $145K in Q3 2025, down 77% year over year and down 11% from the previous quarter.
Gross margin was 81.9%, up 28.3 points from a year earlier. Operating costs exceeded revenue by $7.0M, an operating margin of -4824.5%. Operating expenses fell 33% while revenue fell 77%. The quarter ended with a net loss of $5.9M, narrower than the previous quarter's $7.7M loss.
Operating cash flow was −$5.9M. Non-cash charges added back $267K of depreciation and amortization and $501K of share-based compensation. Working capital and other items used $786K. Capital expenditures of $75K exceeded it, leaving free cash flow of −$6.0M.
Questions
What was Co-Diagnostics' revenue in the third quarter 2025?
Co-Diagnostics (CODX) reported revenue of $145K for the third quarter 2025 (Q3 2025), -77% from a year earlier and -11% from the quarter before.
Source: Co-Diagnostics 10-Q on SEC EDGAR.